Business
Rigel Provides Business Update and 2026 Outlook
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2025, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2026.
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"In the dose escalation phase of the Phase 1b study of R289 in patients with lower-risk MDS, R289 continues to be generally well tolerated. RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group","length":298,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment in the dose expansion phase of the Phase 1b study is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 Outlook: Rigel anticipates full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year ","length":194,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":868,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2025, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2026.","length":424,"tagName":"p"},{"type":"image","alt":"Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":360,"height":216,"url":"https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r.iSRYgiUJa1Zyjd9KnCpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQyMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea","width":360,"height":216}},"href":"https://mma.prnewswire.com/media/681135/Rigel_R_Logo.html","hrefExternal":true,"...